Feb 03, 2020
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
Jan 30, 2020
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
Jan 15, 2020
Inovio Welcomes Biotech Leader to its Board of Directors
Jan 06, 2020
Inovio Provides Update on Clinical Program Plans for 2020
Nov 25, 2019
Inovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
Nov 15, 2019
Inovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
Nov 12, 2019
Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results
Oct 29, 2019
Inovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
Sep 17, 2019
Inovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
Sep 03, 2019
Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
Aug 19, 2019
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
Aug 08, 2019
Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
Aug 06, 2019
Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea
Jul 30, 2019
Inovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019
Jul 25, 2019
Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases
Jul 08, 2019
Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)
Jun 26, 2019
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
Jun 10, 2019
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
May 21, 2019
Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial
May 06, 2019
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100